- Home
- ATHA vs SYTA Comparison
ATHA vs SYTA Comparison
Compare ATHA & SYTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- SYTA
- Stock Information
- Founded
- ATHA 2011
- SYTA N/A
- Country
- ATHA United States
- SYTA Canada
- Employees
- ATHA N/A
- SYTA 24
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- SYTA Telecommunications Equipment
- Sector
- ATHA Health Care
- SYTA Telecommunications
- Exchange
- ATHA Nasdaq
- SYTA Nasdaq
- Market Cap
- ATHA 10.6M
- SYTA 10.7M
- IPO Year
- ATHA 2020
- SYTA 2020
- Fundamental
- Price
- ATHA $0.31
- SYTA $2.03
- Analyst Decision
- ATHA Buy
- SYTA
- Analyst Count
- ATHA 4
- SYTA 0
- Target Price
- ATHA $11.25
- SYTA N/A
- AVG Volume (30 Days)
- ATHA 1.3M
- SYTA 2.0M
- Earning Date
- ATHA 07-31-2025
- SYTA 08-15-2025
- Dividend Yield
- ATHA N/A
- SYTA N/A
- EPS Growth
- ATHA N/A
- SYTA N/A
- EPS
- ATHA N/A
- SYTA N/A
- Revenue
- ATHA N/A
- SYTA $11,740,024.00
- Revenue This Year
- ATHA N/A
- SYTA $18.41
- Revenue Next Year
- ATHA N/A
- SYTA N/A
- P/E Ratio
- ATHA N/A
- SYTA N/A
- Revenue Growth
- ATHA N/A
- SYTA 33.58
- 52 Week Low
- ATHA $0.22
- SYTA $0.93
- 52 Week High
- ATHA $3.67
- SYTA $162.90
- Technical
- Relative Strength Index (RSI)
- ATHA 49.52
- SYTA 43.33
- Support Level
- ATHA $0.29
- SYTA $1.83
- Resistance Level
- ATHA $0.35
- SYTA $2.30
- Average True Range (ATR)
- ATHA 0.03
- SYTA 0.32
- MACD
- ATHA -0.00
- SYTA -0.13
- Stochastic Oscillator
- ATHA 14.10
- SYTA 12.12
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About SYTA Siyata Mobile Inc.
Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.